Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMILLA: Cabozantinib + Durvalumab +/- Tremelimumab in Advanced GI Malignancies
NCT03539822Phase 2Recruiting
- Start
- Oct 2018
- Primary completion
- Jun 2028
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabozantinib and durvalumab in gastric cancer (GC), esophageal adenocarcinoma (EAC), hepatocellular carcinoma (HCC) and 1 more (4 cohorts). Primary endpoints: Maximum Tolerated Dose at 9 months and Overall Response Rate. Started Oct 2018; status: recruiting.
02
Drugs
cabozantinibdurvalumab
03
Conditions
gastric cancer (GC)esophageal adenocarcinoma (EAC)hepatocellular carcinoma (HCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03539822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03539822.